JP2019529476A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019529476A5 JP2019529476A5 JP2019516536A JP2019516536A JP2019529476A5 JP 2019529476 A5 JP2019529476 A5 JP 2019529476A5 JP 2019516536 A JP2019516536 A JP 2019516536A JP 2019516536 A JP2019516536 A JP 2019516536A JP 2019529476 A5 JP2019529476 A5 JP 2019529476A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- cabozantinib
- urinary tract
- cell carcinoma
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662400481P | 2016-09-27 | 2016-09-27 | |
| US62/400,481 | 2016-09-27 | ||
| US201762457952P | 2017-02-12 | 2017-02-12 | |
| US62/457,952 | 2017-02-12 | ||
| US201762459340P | 2017-02-15 | 2017-02-15 | |
| US62/459,340 | 2017-02-15 | ||
| US201762552296P | 2017-08-30 | 2017-08-30 | |
| US62/552,296 | 2017-08-30 | ||
| PCT/US2017/053766 WO2018064191A1 (en) | 2016-09-27 | 2017-09-27 | Method of treating urothelial carcinoma and other genitourinary malignancies using n-(4-(6,7-dimethoxyquinolin-4-yloxy)-phenyl)-n'(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019529476A JP2019529476A (ja) | 2019-10-17 |
| JP2019529476A5 true JP2019529476A5 (enExample) | 2020-11-12 |
Family
ID=60190916
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019516536A Withdrawn JP2019529476A (ja) | 2016-09-27 | 2017-09-27 | Ｎ−（４−（６，７−ジメトキシキノリン−４−イルオキシ）フェニル）−ｎ’−（４−フルオロフェニル）シクロプロパン−１，１−ジカルボキサミドを用いた尿路上皮癌及び他の尿生殖器悪性腫瘍の治療方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20210275515A1 (enExample) |
| EP (1) | EP3518928A1 (enExample) |
| JP (1) | JP2019529476A (enExample) |
| AU (1) | AU2017336547A1 (enExample) |
| CA (1) | CA3038500A1 (enExample) |
| MA (1) | MA46355A (enExample) |
| WO (1) | WO2018064191A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3589754T3 (pl) | 2017-03-01 | 2023-10-09 | F. Hoffmann-La Roche Ag | Sposoby diagnostyczne i terapeutyczne w chorobach nowotworowych |
| HRP20251184T1 (hr) | 2018-01-26 | 2025-12-05 | Exelixis, Inc. | Spojevi za liječenje poremećaja ovisnih o kinazi |
| AU2019285066B2 (en) | 2018-06-15 | 2024-06-13 | Handa Pharmaceuticals, Inc. | Kinase inhibitor salts and compositions thereof |
| EP3867646A1 (en) * | 2018-10-18 | 2021-08-25 | F. Hoffmann-La Roche AG | Diagnostic and therapeutic methods for sarcomatoid kidney cancer |
| AU2021318134A1 (en) * | 2020-07-31 | 2023-03-02 | Exelixis, Inc. | Combinations for the treatment of cancer |
| CA3202761A1 (en) * | 2020-11-25 | 2022-06-02 | Nanocopoeia, Llc | Amorphous cabozantinib particles and uses thereof |
| US20220280500A1 (en) * | 2021-02-19 | 2022-09-08 | Slayback Pharma Llc | Pharmaceutical compositions of cabozantinib |
| US20220387418A1 (en) * | 2021-02-19 | 2022-12-08 | Slayback Pharma Llc | Pharmaceutical compositions of cabozantinib |
| US20220362235A1 (en) * | 2021-02-19 | 2022-11-17 | Slayback Pharma Llc | Pharmaceutical compositions of cabozantinib |
| US11590122B2 (en) | 2021-02-19 | 2023-02-28 | Slayback Pharma Llc | Pharmaceutical compositions of cabozantinib |
| CN120417903A (zh) | 2023-01-31 | 2025-08-01 | 汉达癌症医药责任有限公司 | 改良的卡博替尼组合物及其使用方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2392564T1 (sl) | 2003-09-26 | 2014-02-28 | Exelixis, Inc. | c-Met modulatorji in postopki uporabe |
| WO2008083319A1 (en) | 2006-12-29 | 2008-07-10 | Il Yang Pharmaceutical Company, Ltd. | Solid state forms of enantiopure ilaprazole |
| CN114209699A (zh) | 2010-07-16 | 2022-03-22 | 埃克塞里艾克西斯公司 | C-met调节剂药物组合物 |
| AR085155A1 (es) | 2011-02-10 | 2013-09-11 | Exelixis Inc | Procesos para preparar compuestos de quinolina y composiciones farmaceuticas que contienen dichos compuestos |
-
2017
- 2017-09-27 US US16/336,724 patent/US20210275515A1/en not_active Abandoned
- 2017-09-27 WO PCT/US2017/053766 patent/WO2018064191A1/en not_active Ceased
- 2017-09-27 MA MA046355A patent/MA46355A/fr unknown
- 2017-09-27 EP EP17791484.3A patent/EP3518928A1/en not_active Withdrawn
- 2017-09-27 CA CA3038500A patent/CA3038500A1/en not_active Abandoned
- 2017-09-27 AU AU2017336547A patent/AU2017336547A1/en not_active Abandoned
- 2017-09-27 JP JP2019516536A patent/JP2019529476A/ja not_active Withdrawn
-
2022
- 2022-11-29 US US18/059,840 patent/US20230130243A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019529476A5 (enExample) | ||
| JP2022022264A5 (enExample) | ||
| CN111065411B (zh) | Pd-1抗体和vegfr抑制剂联合治疗小细胞肺癌的用途 | |
| JP2017039771A5 (enExample) | ||
| JP2022031403A5 (enExample) | ||
| CN104519887B (zh) | 包含B‑Raf抑制剂、EGFR抑制剂和任选PI3Kα抑制剂的药物组合 | |
| JP4297620B2 (ja) | 肝細胞性腫瘍処置用薬剤 | |
| AU2021307410A1 (en) | Combination therapy for treating abnormal cell growth | |
| KR20240041978A (ko) | 비정상적 세포 성장을 치료하기 위한 조합 요법 | |
| CN101969931A (zh) | 包含霉酚酸的调节释放药物组合物及其方法 | |
| JP2017537105A5 (enExample) | ||
| JP2021502415A (ja) | 癌の処置のためのアパチニブを用いる併用療法 | |
| JP2012531430A5 (enExample) | ||
| CN101669941A (zh) | 一种联合用药治疗恶性肿瘤的方法以及抗恶性肿瘤的药物 | |
| CN105873583A (zh) | 用于降低慢性肾病患者的心力衰竭的枸橼酸铁 | |
| JP2019508433A5 (enExample) | ||
| WO2018072743A1 (zh) | Pd-1抗体与ido抑制剂联合在制备抗肿瘤的药物中的用途 | |
| WO2023061472A1 (zh) | 抗her2抗体药物偶联物和酪氨酸激酶抑制剂联合在制备治疗肿瘤的药物中的用途 | |
| CN109663145A (zh) | 一种碘油靶向药物复合物 | |
| JPWO2021021563A5 (enExample) | ||
| JPWO2021007146A5 (enExample) | ||
| JP2020512292A5 (enExample) | ||
| CN115944743A (zh) | 一种富马酸伏诺拉生组合物及其制备方法 | |
| WO2024153229A1 (zh) | 抗her2抗体药物偶联物治疗乳腺癌 | |
| TWI822897B (zh) | 一種抗pd-1抗體和法米替尼聯合在製備治療腫瘤的藥物中的用途 |